Annual report pursuant to Section 13 and 15(d)

License Agreements - Additional Information (Detail)

v3.24.1
License Agreements - Additional Information (Detail) - USD ($)
 12 Months Ended 90 Months Ended
Jan. 22, 2018
May 14, 2015
Dec. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Jul. 31, 2016
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Cash     $ 400,000 $ 400,000    
Fair value of the contingent consideration     528,000 528,000  
Loss on contingent consideration     528,000      
University of Bristol [Member]            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Maximum amount payable under license agreement, tied to milestones           $ 3,200,000
Payments under license agreement       125,000    
University of Bristol [Member] | Amendment to the University of Bristol License Agreement [Member]            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Maximum amount payable under license agreement, tied to milestones $ 1,700,000          
Payments under license agreement $ 37,500          
Sopharma [Member] | Share Purchase Agreement [Member]            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Percentage of outstanding shares acquired   75.00%        
Cash   $ 2,000,000        
Deferred payment   $ 2,000,000        
Fair value of the contingent consideration     500,000 $ 500,000    
Loss on contingent consideration     $ 500,000